• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,958.05 454.45
( 0.59%)
Global Indices
Nasdaq
52,357.11 -589.04
(-1.11%)
Dow Jones
7,503.65 -21.20
(-0.28%)
Hang Seng
67,213.51 -1,043.45
(-1.53%)
Nikkei 225
10,469.05 -196.83
(-1.85%)
Forex
USD-INR
95.15 -0.21
(-0.22%)
EUR-INR
108.73 -0.26
(-0.24%)
GBP-INR
127.27 -0.11
(-0.09%)
JPY-INR
0.59 0.00
(-0.14%)

EQUITY - MARKET SCREENER

HDFC Bank Ltd
Industry :  Banks - Private Sector
BSE Code
ISIN Demat
Book Value()
500180
INE040A01034
362.5379585
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
HDFCBANK
16.72
1248200.59
EPS(TTM)
Face Value()
Div & Yield %
48.48
1
1.91
 

setco automotive ltd
Dr Reddy's Laboratories gains for sixth straight session
Jun 29,2026
The stock has advanced 9.05% over six trading sessions. It has gained 7.92% in the last three months and 6.33% over the past year.

On 25 June 2026, the drug maker informed the exchanges that the US Food and Drug Administration (USFDA) had completed a Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderabad. The inspection was conducted between 16 June 2026 and 25 June 2026.

Following the inspection, the USFDA issued a Form 483 with seven observations. Dr. Reddy's said it will respond to the observations within the stipulated timeline.

The company said the inspection is a continuation of earlier inspections and related disclosures made to the stock exchanges on 12 October 2023 and 13 September 2025.

Hyderabad-based Dr Reddy’s Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

The company reported a 86.14% decline in consolidated net profit to Rs 220.9 crore on 11.51% drop in revenue from operations to Rs 7,546.4 crore in Q4 FY26 over Q4 FY25.